Cancer therapy using tumor-associated antigens to reduce side effects

Siu, David

doi:10.1007/s10238-009-0047-z

Cited by 10 publications

(13 citation statements)

References 105 publications

(145 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TAAs are overexpressed on cancer cells, whereas they are present in fewer numbers or not expressed on normal cells. Furthermore, therapies specifically targeting TAAs have become very popular in cancer therapy as they cause fewer side effects than traditional cancer regimens [15,16].…”

Section: T and B Lymphocytesmentioning

confidence: 99%

Lymphocyte subpopulation and dendritic cell phenotyping during antineoplastic therapy in human solid tumors

et al. 2010

View full text Add to dashboard Cite

Patients with cancer show variable levels of immunosuppression at the time of the presentation, and cytotoxic antineoplastic therapy is the primary contributor to the clinical immunodeficiency often observed during the course of the disease. In both hematological and solid tumors, this phenomenon is primarily related to the T-cell depletion associated with inhibition of dendritic cell ability to induce both primary and secondary T- and B-cell responses. Complete restoration of immunocompetence following antineoplastic therapy implicates the progressive recovery of various cell subpopulations, and it is a complex process that also depends on the type, the dose, the scheduling, and the associations of the employed drugs. In the era of target therapies, several antiangiogenic drugs are increasingly used in combination with standard chemotherapy in the treatment of advanced solid tumors. Their clinical efficacy has been recently related not only to the specific antiangiogenic properties but also to an indirect hypothetical effect on the host immune system. In the present work, we have reviewed the most recent information regarding (1) the capacity of standard antineoplastic therapy to induce and maintain an immunodeficiency in patients with solid tumors and (2) the influence of the antiangiogenic treatment in association with standard chemotherapy on lymphocyte and dendritic cell subsets and the possible resulting additional antitumor mechanism.

show abstract

Section: T and B Lymphocytesmentioning

confidence: 99%

Lymphocyte subpopulation and dendritic cell phenotyping during antineoplastic therapy in human solid tumors

et al. 2010

View full text Add to dashboard Cite

show abstract

“…When constructing ternary structure for NPs, some factors, such as antigen or receptor expression, internalization of targeted conjugates, and potential of nanomaterials to overcome drug resistance, must be considered to create more efficient delivery systems. Ideally, cell-surface antigens and receptors should have several properties that render them particularly suitable tumor-specific targets [91]. First, they should be expressed exclusively and homogeneously on tumor cells and not expressed on normal cells.…”

Section: Nanotechnology As a Strategy For Cancer Controlmentioning

confidence: 99%

Nanoformulation of natural products for prevention and therapy of prostate cancer

et al. 2013

View full text Add to dashboard Cite

There is a need for developing improved therapeutic options for the management of prostate cancer, able to inhibit proliferation of precancerous and malignant lesions and/or to improve the effectiveness of conventional chemopreventive and chemotherapeutic agents. In this perspective, application of nanotechnology based strategies for the delivery of natural compounds for effective management of the disease is being actively researched. Here, after highlighting the most promising natural compounds for chemoprevention and chemotherapy of prostate cancer, the state of the art nanotherapeutics and the recent proof-of-concept of “nanochemoprevention”, as well as the clinical development of promising targeted nanoprototypes for use in the prostate cancer treatment are being discussed.

show abstract

“…This increases interest in agents such as mAbs that are less inherently toxic than the conventional therapies,24,25 and so safer for widespread delivery. For tumor outside the brain, a complementary attraction is that most therapies are thought most likely to succeed against micro-tumor, as opposed to larger masses 26.…”

Section: The Target: Tumor In the Brainmentioning

confidence: 99%

“…2 ). 24,30 Fortunately, shared molecules can serve as practical tumor targets and this is true for each molecule targeted by the mAbs in Table 1 .…”

Section: The Magic: What Tumor-specific Can Meanmentioning

confidence: 99%

See 1 more Smart Citation

Monoclonal antibodies in neuro-oncology

Lampson¹

2011

mAbs

119

View full text Add to dashboard Cite

Monoclonal antibodies (mAbs) are used with increasing success against many tumors, but for brain tumors the blood-brain barrier (BBB) is a special concern. The BBB prevents antibody entry to the normal brain; however, its role in brain tumor therapy is more complex. The BBB is closest to normal at micro-tumor sites; its properties and importance change as the tumor grows. In this review, evolving insight into the role of the BBB is balanced against other factors that affect efficacy or interpretation when mAbs are used against brain tumor targets. As specific examples, glioblastoma multiforme (GBM), primary central nervous system lymphoma (PCNSL) and blood-borne metastases from breast cancer are discussed in the context of treatment, respectively, with the mAbs bevacizumab, rituximab and trastuzumab, each of which is already widely used against tumors outside the brain. It is suggested that success against brain tumors will require getting past the BBB in two senses: physically, to better attack brain tumor targets, and conceptually, to give equal attention to problems that are shared with other tumor sites.

show abstract

Cancer therapy using tumor-associated antigens to reduce side effects

Cited by 10 publications

References 105 publications

Lymphocyte subpopulation and dendritic cell phenotyping during antineoplastic therapy in human solid tumors

Lymphocyte subpopulation and dendritic cell phenotyping during antineoplastic therapy in human solid tumors

Nanoformulation of natural products for prevention and therapy of prostate cancer

Monoclonal antibodies in neuro-oncology

Contact Info

Product

Resources

About